Method for evaluating the potential of ¹⁴C labeled plant polyphenols to cross the blood–brain barrier using accelerator mass spectrometry

详细信息    查看全文

• 作者：Elsa M. Janle ; Mary Ann Lila ; Michael Grannan ; Lauren Wood ; Aine Higgins ; Gad G. Yousef ; R ; y B. Rogers ; Helen Kim ; George S. Jackson ; Connie M. Weaver
• 关键词：Blood– ; brain barrier ; Grape polyphenols ; Pharmacokinetics ; Accelerator mass spectrometry ; 14C labeled plant polyphenols
• 刊名：Nuclear Instruments and Methods in Physics Research Section B: Beam Interactions with Materials and Atoms
• 出版年：2010
• 出版时间：April 2010
• 年：2010
• 卷：268
• 期：7-8
• 页码：1313-1316
• 全文大小：270 K

文摘

Bioactive compounds in botanicals may be beneficial in preventing age-related neurodegenerative diseases, but for many compounds conventional methods may be inadequate to detect if these compounds cross the blood–brain barrier or to track the pharmacokinetics in the brain. By combining a number of unique technologies it has been possible to utilize the power of AMS to study the pharmacokinetics of bioactive compounds in the brain at very low concentrations. ¹⁴C labeled compounds can be biosynthesized by plant cell suspension cultures co-incubated with radioisotopically-labeled sucrose and isolated and separated into a series of bioactive fractions.

To study the pharmacokinetics and tissue distribution of ¹⁴C labeled plant polyphenols, rats were implanted with jugular catheters, subcutaneous ultrafiltration probes and brain microdialysis probes. Labeled fractions were dosed orally. Interstitial fluid (ISF) and brain microdialysate samples were taken in tandem with blood samples. It was often possible to determine ¹⁴C in blood and ISF with a β-counter. However, brain microdialysate samples ¹⁴C levels on the order of 10⁷ atoms/sample required AMS technology. The Brain Microdialysate_AUC/Serum_AUC ranged from .021- to .029, with the higher values for the glycoside fractions. By using AMS in combination with traditional methods, it is possible to study uptake by blood, distribution to ISF and determine the amount of a dose which can reach the brain and follow the pharmacokinetics in the brain.